Safety and Utility of Quantitative Sensory Testing among Adults with Sickle Cell Disease: Indicators of Neuropathic Pain?

Pain Practice

Volumn 16, Issue 3, 2016, Pages 282-293

  Ezenwa, Miriam O ^a   Molokie, Robert E ^a,b   Wang, Zaijie Jim ^a   Yao, Yingwei ^a   Suarez, Marie L ^a   Pullum, Cherese ^a   Schlaeger, Judith M ^a   Fillingim, Roger B ^c   Wilkie, Diana J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

Author keywords

Neuropathic pain; Pain; PAINReportIt; Quantitative sensory testing; Sickle cell

Indexed keywords

ADULT; ANALYZER; ARTICLE; CLINICAL ARTICLE; CONSTRUCT VALIDITY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MECHANICAL QUANTITATIVE SENSORY TESTING; NEUROPATHIC PAIN; QUALITY OF LIFE; QUESTIONNAIRE; SAFETY; SELF REPORT; SENSITIZATION; SENSORY SYSTEM EXAMINATION; SICKLE CELL ANEMIA; THERMAL QUANTITATIVE SENSORY TESTING; VON FREY MICROFILAMENT; ADVERSE EFFECTS; AFRICAN AMERICAN; COMPLICATION; HEAT; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PERIPHERAL NERVE; PHYSICAL STIMULATION; PROCEDURES; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; ANEMIA, SICKLE CELL; CROSS-SECTIONAL STUDIES; FEMALE; HOT TEMPERATURE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PERIPHERAL NERVES; PHYSICAL STIMULATION; QUALITY OF LIFE; SELF REPORT; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84959452326     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12279     Document Type: Article

References (42)

1. Yusuf HR, Atrash HK, Grosse SD, Parker CS, Grant AM. Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007. Am J Prev Med 2010;38:S536-S541.
2. Ballas S. Sickle cell pain. Seattle: IASP Press; 1998.
3. Benjamin LJ, Dampier CD, Jacox AK, et al. Guidelines for the management of acute and chronic pain in sickle-cell disease. Glenview, IL: American Pain Society; 1999.
4. Wilkie DJ, Molokie R, Boyd-Seal D, et al. Patient-reported outcomes: nociceptive and neuropathic pain and pain barriers in adult outpatients with sickle cell disease. J Natl Med Assoc. 2010;102:18-27.
5. Kohli DR, Li Y, Khasabov SG, et al. Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood 2010;116:456-465.
6. Hillery CA, Kerstein PC, Vilceanu D, et al. Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. Blood 2011;118:3376-3383.
7. Wang ZJ, Wilkie DJ, Molokie R. Neurobiological mechanisms of pain in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2010;2010:403-408.
8. Zappia KJ, Garrison SR, Hillery CA, Stucky CL. Cold hypersensitivity increases with age in mice with sickle cell disease. Pain 2014;155:2476-2485.
9. Backonja MM, Walk D, Edwards RR, et al. Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory abnormalities. Clin J Pain 2009;25:641-647.
10. Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 2010;17:1010-1018.
11. Lanzkron S, Carroll CP, Haywood C Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol 2010;85:797-799.
12. Brandow AM, Stucky CL, Hillery CA, Hoffmann RG, Panepinto JA. Patients with sickle cell disease have increased sensitivity to cold and heat. Am J Hematol 2012;88:37-43.
13. O'Leary JD, Crawford MW, Odame I, Shorten GD, McGrath PA. Thermal pain and sensory processing in children with sickle cell disease. Clin J Pain 2014;30:244-250.
14. Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain. Pain 2007;127:199-203.
15. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6:149-158.
16. Gray P. Acute neuropathic pain: diagnosis and treatment. Curr Opin Anaesthesiol. 2008;21:590-595.
17. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004;108:248-257.
18. Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ 3rd. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med. 2009;10:586-593.
19. Wilkie DJ, Judge MK, Berry DL, Dell J, Zong S, Gilespie R. Usability of a computerized PAINReportIt in the general public with pain and people with cancer pain. J Pain Symptom Manage 2003;25:213-224.
20. Melzack R. The McGill pain questionnaire: Major properties and scoring methods. Pain 1975;1:277-299.
21. Holroyd KA, Holm JE, Keefe FJ, et al. A multi-center evaluation of the McGill Pain Questionnaire: results from more than 1700 chronic pain patients. Pain 1992;48:301-311.
22. Pearce J, Morley S. An experimental investigation of the construct validity of the McGill Pain Questionnaire. Pain 1989;39:115-121.
23. Huang HY, Wilkie DJ, Zong SP, et al. Developing a computerized data collection and decision support system for cancer pain management. Comput Inform Nurs. 2003;21:206-217.
24. Jha A, Suarez ML, Ferrans CE, Molokie R, Kim YO, Wilkie DJ. Cognitive testing of PAINReportIt in adult African Americans with sickle cell disease. Comput Inform Nurs. 2010;28:141-150.
25. Bouhassira D. Neuropathic pain: the clinical syndrome revisited. Acta Neurol Belg 2001;101:47-52.
26. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-164.
27. Jenkinson C, Wright L, Coulter A. Criterion validity and reliability of the SF-36 in a population sample. Qual Life Res 1994;3:7-12.
28. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-263.
29. Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
30. Collins LM, Schafer JL, Kam CM. A comparison of inclusive and restrictive strategies in modern missing data procedures. Psychol Methods 2001;6:330-351.
31. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008;148:94-101.
32. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood 2012;120:3647-3656.
33. Smith V. Reference Values for Quantitative Sensory Testing (QST) in Healthy Individuals [Honor's College]. Chicago, IL: Biobehavioral Health Science, University of Illinois at Chicago; 2011.
34. McKemy DD. The molecular and cellular basis of cold sensation. ACS Chem Neurosci. 2013;4:238-247.
35. Defrin R, Ohry A, Blumen N, Urca G. Sensory determinants of thermal pain. Brain 2002;125:501-510.
36. Hiura A. Is thermal nociception only sensed by the capsaicin receptor, TRPV1? Anat Sci Int. 2009;84:122-128.
37. Campbell CM, Edwards RR, Fillingim RB. Ethnic differences in responses to multiple experimental pain stimuli. Pain 2005;113:20-26.
38. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004;11:153-162.
39. Haanpaa M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152:14-27.
40. Molokie RE, Wang ZJ, Wilkie DJ. Presence of neuropathic pain as an underlying mechanism for pain associated with cold weather in patients with sickle cell disease. Med Hypotheses 2011;77:491-493.
41. Molokie RE, Wilkie DJ, Wittert H, et al. Mechanism-driven phase I translational study of trifluoperazine in adults with sickle cell disease. Eur J Pharmacol 2014;723:419-424.
42. Hagander LG, Midani HA, Kuskowski MA, Parry GJ. Quantitative sensory testing: effect of site and skin temperature on thermal thresholds. Clin Neurophysiol 2000;111:17-22.